Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection

References

• Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother 2011;12(13):2025-40
   PubMed Web of Science ®Google Scholar
• Zhang NP, Reijnders JG, Perquin M, et al. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. J Viral Hepat 2011;18(7):e252-7
   PubMedGoogle Scholar
• Tang H, McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA 2001;98(4):1841-6
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678-86
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73
   PubMed Web of Science ®Google Scholar
• Vigano M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11(3):285-300
   PubMed Web of Science ®Google Scholar
• Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: mechanisms and mutation sites. Hepatol Res 2011;41(11):1017-24
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66(3):1153-8
   PubMed Web of Science ®Google Scholar
• Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014;39(1):35-46
   PubMedGoogle Scholar
• Shiffman ML, Pol S, Rostaing L, et al. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. J Clin Pharmacol 2011;51(9):1293-301
   PubMedGoogle Scholar
• Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13(2):245-54
   PubMed Web of Science ®Google Scholar
• Starrett JE Jr, Tortolani DR, Russell J, et al. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J Med Chem 1994;37(12):1857-64
   PubMedGoogle Scholar
• Zhou YL, Wang XC, Wu YT, et al. Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010;24(5):362-3
   PubMedGoogle Scholar
• Ray AS, Vela JE, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004;68(9):1825-31
   PubMedGoogle Scholar
• Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000;7(1):79-83
   PubMed Web of Science ®Google Scholar
• Birkus G, Gibbs CS, Cihlar T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J Viral Hepat 2003;10(1):50-4
   PubMedGoogle Scholar
• Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 1995;39(10):2304-8
   PubMed Web of Science ®Google Scholar
• Nekvindova J, Masek V, Veinlichova A, et al. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica 2006;36(12):1165-77
   PubMed Web of Science ®Google Scholar
• Janke D, Mehralivand S, Strand D, et al. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat 2008;29(5):659-69
   PubMed Web of Science ®Google Scholar
• Mandikova J, Volkova M, Pavek P, et al. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates. Toxicology 2013;311(3):135-46
   PubMedGoogle Scholar
• Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008;47(6):1863-71
   PubMed Web of Science ®Google Scholar
• Adefovir dipivoxil for the treatment of chronic hepatitis B. Available from: www.fda.gov/ohrms/dockets/ac/02/briefing/3885B1_01_Gilead.pdf
   Google Scholar
• Hadziyannis SJ, Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004;2(4):475-83
   PubMedGoogle Scholar
• Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008;48(4):512-17
   PubMedGoogle Scholar
• Sokal E, Kelly D, Wirth S, et al. The Pharmacokinetics (Pk) and safety of a single dose of adefovir dipivoxil (Adv) in children and adolescents (aged 2-17) with chronic hepatitis B. J Pediatr Gastroenterol Nutr 2004;39(2):226-7
   Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9):808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800-7
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44(1):108-16
   PubMedGoogle Scholar
• Minde Z, Yimin M, Guangbi Y, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int 2012;32(1):137-46
   PubMedGoogle Scholar
• Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126(1):91-101
   PubMed Web of Science ®Google Scholar
• Sun J, Xie Q, Tan D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 2014;59(4):1283-92
   PubMed Web of Science ®Google Scholar
• Kim SS, Cheong JY, Lee D, et al. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. J Med Virol 2012;84(1):18-25
   PubMedGoogle Scholar
• Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48(3):750-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131(6):1743-51
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J 2012;31(6):578-82
   PubMed Web of Science ®Google Scholar
• US FDA Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera.cfm
   Google Scholar
• Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38(6):1419-27
   PubMed Web of Science ®Google Scholar